[
    {
        "file_name": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_DevelopmentAgreement.txt",
        "perturbation": [
            {
                "type": "Ambiguities - In Text Contradiction",
                "original_text": "1.1.22 \"Calendar Year\" means each successive period of twelve (12) months commencing on January 1 and ending on December 31; provided, that, (a) the first Calendar Year shall begin on the Effective Date and end on December 31 of the Calendar Year in which the Effective Date falls, and (b) the final Calendar Year shall end on the last day of the Term.",
                "changed_text": "1.1.22 \"Calendar Year\" means each period determined by SFJ, not necessarily twelve months, commencing on a date SFJ chooses. The end date will also be picked by SFJ; provided, that, (a) the first Calendar Year shall begin on the Effective Date and end on December 31 of the Calendar Year in which the Effective Date falls, and (b) the final Calendar Year shall end on the last day of the Term.",
                "explanation": "This change introduces ambiguity by giving SFJ the ability to arbitrarily define 'Calendar Year', whereas another section in this document has the initial and original definition. This creates an internal contradiction if another part of the contract enforces the initial definition. This would lead to disputes over payment schedules tied to 'Calendar Year'.",
                "location": "Section 1.1.22"
            },
            {
                "type": "Ambiguities - In Text Contradiction",
                "original_text": "3.12 Commercially Reasonable Efforts.\n\n3.12.1 Timely performance of the Clinical Trials and receipt of Regulatory Approval is important to the success of this Agreement. Each Party will use Commercially Reasonable Efforts to complete the Clinical Trials according to the Timeline and, if the Clinical Trials is successful, to obtain Regulatory Approval, in such Party's Territory. In the event that either Party fails to complete the Clinical Trials in their respective Territory according to the Timeline and this failure is not cured as set forth in Section 14.2.1, the other Party may terminate this Agreement pursuant to Section 14.2.1, or following discussion by the JSC that such Party failed to use Commercially Reasonable Efforts, the other Party may assume the roles and responsibilities of such Party; provided that in the event of such failure by SFJ, SFJ will remain obligated to pay the costs under Section 4.2.2(ii).",
                "changed_text": "3.12 Commercially Reasonable Efforts.\n\n3.12.1 Timely performance of the Clinical Trials and receipt of Regulatory Approval is important to the success of this Agreement. Each Party will use commercially acceptable efforts to complete the Clinical Trials according to the Timeline and, if the Clinical Trials is successful, to obtain Regulatory Approval, in such Party's Territory. In the event that either Party fails to complete the Clinical Trials in their respective Territory according to the Timeline and this failure is not cured as set forth in Section 14.2.1, the other Party may terminate this Agreement pursuant to Section 14.2.1, or following discussion by the JSC that such Party failed to use Commercially Acceptable Efforts, the other Party may assume the roles and responsibilities of such Party; provided that in the event of such failure by SFJ, SFJ will remain obligated to pay the costs under Section 4.2.2(ii).",
                "explanation": "The key term 'Commercially Reasonable Efforts' which is a pre-defined term is now replaced with 'commercially acceptable efforts'. This can introduce ambiguities.",
                "location": "Section 3.12.1"
            },
            {
                "type": "Ambiguities - In Text Contradiction",
                "original_text": "5.2.4 Decision-Making. PB shall retain sole decision-making authority over all matters within the scope of the JSC's oversight other than the matters described in the foregoing 5.2.2. The unanimous approval of the JSC will be required with respect to all matters within its decision-making authority as described in the foregoing Section 5.2.2. The JSC Representatives of each Party will collectively have one (1) vote. The presence of at least one of each Party's JSC representatives constitutes a quorum for the conduct of business at any JSC meeting, and no vote of the JSC may be taken without a quorum present. If the JSC cannot reach consensus on an issue for which it has decision-making authority, then PB shall have the final decision-making authority, provided that if SFJ disagrees with any such PB decision with regard to any of the matters set forth in Section 5.2.2, then, at SFJ's request, the matter shall be escalated to the Executive Officers for attempted resolution by good faith negotiations during a period of [***]. If, notwithstanding such good faith negotiations, the Executive Officers fail to resolve such matter prior to expiration of such [***] negotiation period, and SFJ in good faith continues to disagree with such PB decision, then SFJ shall have the right to terminate this Agreement as provided in Section 14.2.10 upon written notice to PB delivered within [***] after expiration of such [***] negotiation period.",
                "changed_text": "5.2.4 Decision-Making. PB shall retain sole decision-making authority over all matters within the scope of the JSC's oversight other than the matters described in the foregoing 5.2.2. Approval of the JSC will be required with respect to all matters within its decision-making authority as described in the foregoing Section 5.2.2. The JSC Representatives of each Party will collectively have one (1) vote. The presence of at least one of each Party's JSC representatives constitutes a quorum for the conduct of business at any JSC meeting, and no vote of the JSC may be taken without a quorum present. If the JSC cannot reach consensus on an issue for which it has decision-making authority, then SFJ shall have the final decision-making authority, provided that if PB disagrees with any such SFJ decision with regard to any of the matters set forth in Section 5.2.2, then, at PB's request, the matter shall be escalated to the Executive Officers for attempted resolution by good faith negotiations during a period of [***]. If, notwithstanding such good faith negotiations, the Executive Officers fail to resolve such matter prior to expiration of such [***] negotiation period, and PB in good faith continues to disagree with such SFJ decision, then PB shall have the right to terminate this Agreement as provided in Section 14.2.10 upon written notice to SFJ delivered within [***] after expiration of such [***] negotiation period.",
                "explanation": "This change introduces ambiguity regarding the 'decision-making authority'. The section now has a contradiction.",
                "location": "Section 5.2.4"
            }
        ]
    }
]